Wire News
Targeting PKC-theta protein: a way to inhibit harmful immune responses?
A concern after leukemia patients receive bone marrow from a person who is not an identical genetic match is that immune cells arising from the donor bone marrow will attack the patient's body. What is needed is a drug that will block such responses but ...
Source:
Journal of Clinical Investigation
Monday, November 9, 2009